Home > Neurology > MS Virtual 2020 > Biomarkers > Serum NfL as biomarker for suboptimal treatment response

Serum NfL as biomarker for suboptimal treatment response

Conference
MS Virtual 2020
Trial
Cohort study, Swiss MS
Serum neurofilament light chain (sNfL) levels are independently associated with clinical and MRI measures of MS disease activity in MS patients [1]. Increased sNfL in patients on disease-modifying therapies for at least 3 months therapy predicted relapses, EDSS worsening, and MRI activity in the subsequent year. Current sNfL levels predicted future clinical disease activity, can detect subclinical disease activity in NEDA-3 patients and may serve as independent of standard metrics for treatment monitoring, and can detect subclinical disease activity in NEDA-3 patients. Participants were 1,062 patients from the Swiss MS Cohort Study, of whom 95.9% had relapsing-remitting MS and 4.1% clinically isolated syndrome (CIS). Median age was 39.7 years, median EDSS 2.0, and median follow-up 5 years. All patients were on disease-modifying therapy for at least 3 months. sNfL was measured every 6 or 12 months with the NF-light® assay. A tota...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on